European Commission Approves Amgen And Allergan's MVASI ® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Marketing Authorization Based on Global Development Program Showing MVASI is Highly Similar to Avastin® (Bevacizumab)
First Biosimilar Bevacizumab Approved in the European Union
THOUSAND OAKS, Calif., Jan. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI® (biosimilar bevacizumab). MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers, including in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma of the colon or rectum; in combination with paclitaxel for metastatic bre...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Allergy | Avastin | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Colon Cancer | Colorectal Cancer | Marketing | Pharmaceuticals